4d Pharma PLC Surges On Research Update

4d Pharma PLC (LON:DDDD) says two products will begin clinical studies in the second quarter of 2015.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

The share price of 4D Pharma (LSE: DDDD) — a pharmaceutical company that focuses on significant new therapeutic areas — is up 9.5% so far today, following publication of a research update.

The update concerns two of 4D Pharma’s products — Blautix, which is a treatment for irritable bowel syndrome (IBS), and Thetanix, which is for the treatment of Paediatric Crohn’s Disease (PCD).  Both products are “live biotherapeutics”, which use live bacteria as the active agent, rather than either of the more traditional approaches of chemicals or biological agents, such as antibodies.

5 Stocks For Trying To Build Wealth After 50

One notable billionaire made 99% of his current wealth after his 50th birthday. And here at The Motley Fool, we believe it is NEVER too late to start trying to build your fortune in the stock market. Our expert Motley Fool analyst team have shortlisted 5 companies that they believe could be a great fit for investors aged 50+ trying to build long-term, diversified portfolios.

Click here to claim your free copy now!

AstraZenecaThe company says that both Blautix and Thetanix are now anticipated to enter clinical studies in Q2 2015.  The studies will primarily be concerned, 4D Pharma says, with evaluating the safety and tolerability of the two products.  

In addition, some clinical effects of Blautix would be assessed in both in healthy volunteers and a small number of symptomatic IBS individuals, whilst some clinical effects of Thetanix would be assessed in PCD patients.

Commenting on the update, Alex Stevenson, the company’s chief scientific officer, commented:

The Blautix and Thetanix trials will represent important milestones for the Company and a new class of therapeutic, designed to treat the underlying causes of diseases rather than just the symptoms. In addition, 4D continues to generate a strong pipeline of live biotherapeutics for other important diseases, using its proprietary MicroRx platform.

At 304p, 4D Pharma’s share price is currently up close to 70% since it listed on AIM in February of this year, since which time the AIM All-Share has fallen over 11%, and the FTSE All-Share has remained flat.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Jon Wallis has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Company Comment

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Rolls-Royce shares are trading for pennies. Should I buy them today?

Just because Rolls-Royce shares cost pennies doesn't make them cheap. Its troubles aren't over yet.

Read more »

Business development to success and FTSE 100 250 350 growth concept.
Investing Articles

8.5% and 9.5% dividend yields! 2 FTSE 100 stocks to buy today

The dividend yields at these brilliant blue-chips sit very close to double digits. I think they could be too good…

Read more »

Investing Articles

Tesco vs Royal Mail: which cheap FTSE 100 share should I buy?

The Tesco and Royal Mail share prices both seem to offer great value at recent levels. So which cheap FTSE…

Read more »

macro shot of computer monitor with FTSE 100 stock market data in trading application
Investing Articles

2 FTSE 100 dividend-paying stocks to buy in an ISA

The deadline for new money going into Stocks and Shares ISAs is just around the corner. Here are two FTSE…

Read more »

Business man on stock market crash financial trade indicator background.
Investing Articles

2 dividend paying banking stocks to combat inflation in 2022

With inflation taking off in the US, the Fed may have to raise rates. Stephen Bhasera believes these banking stocks…

Read more »

Various denominations of notes in a pile
Investing Articles

A high-dividend stock I’d buy now

Why this high-dividend stock is potentially more than just a sleepy cash-cow business and growth looks set to kick in…

Read more »

Investing Articles

2 FTSE 100 dividend stocks I’d aim to never sell

I wouldn't try to hold all my investments forever, but these two FTSE 100 dividend stocks both have many qualities…

Read more »

Scene depicting the City of London, home of the FTSE 100
Investing Articles

With £2,000 to invest, I’d buy these FTSE 100 shares with big dividends

Several FTSE 100 shares pay out big dividends, but I'd start my research with these defensive operators in a growing…

Read more »